Theriva Biologics announces 1-for-25 reverse stock split

Theriva Biologics announced a reverse stock split of its issued and outstanding common stock at a ratio of one share of common stock for every twenty five shares of common stock, effective as of 12:01 a.m. (Eastern Time) on August 26. The company’s common stock will begin trading on a split-adjusted basis when the market opens on August 26. The reverse stock split was authorized by the company’s Board of Directors on August 15. Pursuant to the laws of the State of Nevada, the company’s state of incorporation, the company’s Board of Directors has the authority to effect a reverse stock split without shareholder approval if the number of authorized shares of common stock and the number of outstanding shares of common stock are proportionally reduced. The company will file a certificate of change to its articles of incorporation, as amended, with the Secretary of State of Nevada to effect the reverse stock split. The company’s common stock will continue to trade on the NYSE American under the stock ticker “TOVX” but will trade under the new CUSIP number 87164U 508.